Heart failure as a risk factor of adverse drug reactions. Part 1: potential changes in pharmacokinetics

The use of many drugs is associated with the risk of adverse drug reactions (ADRs), including those that increase mortality and / or morbidity and / or seek medical help or hospitalization, so called «drug-induced diseases» (DID). There is a number of factors that increase the risk of DID (risk fact...

Full description

Saved in:
Bibliographic Details
Published in:Kachestvennai͡a︡ klinicheskai͡a︡ praktika no. 4; pp. 53 - 59
Main Authors: Pereverzev, A. P., Ostroumova, O. D.
Format: Journal Article
Language:English
Russian
Published: Izdatelstvo OKI 13.02.2022
Subjects:
безопасность
лекарственно-индуцированные заболевания
лекарственные средства
нежелательные реакции
сердечная недостаточность
фармакокинетика
ISSN:2588-0519, 2618-8473
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The use of many drugs is associated with the risk of adverse drug reactions (ADRs), including those that increase mortality and / or morbidity and / or seek medical help or hospitalization, so called «drug-induced diseases» (DID). There is a number of factors that increase the risk of DID (risk factors) including comorbid diseases (for example, chronic kidney disease, hepatic impairment, obesity etc.). These pathologic conditions induce changes in pharmacokinetics (PK) and pharmacodynamics of drugs, thereby increasing the risk of ADRs. One of these diseases is heart failure (HF). Most studies of PK changes were conducted among patients with LVEF from 40 to 45 %, and excluded patients with concomitant diseases that could affect the PK of drugs (for example, serious liver and / or kidney diseases), therefore in polymorbid patients, trial findings may not be applicable. HF may be associated with a decrease in bioavailability, a decrease in volume of distribution, a change in the activity of cytochrome P450 isoenzymes, etc. Individual dose and dosage regimen adjustment can significantly reduce risks, improve the quality of medical care and improve the prognosis in patients with heart failure.
AbstractList The use of many drugs is associated with the risk of adverse drug reactions (ADRs), including those that increase mortality and / or morbidity and / or seek medical help or hospitalization, so called «drug-induced diseases» (DID). There is a number of factors that increase the risk of DID (risk factors) including comorbid diseases (for example, chronic kidney disease, hepatic impairment, obesity etc.). These pathologic conditions induce changes in pharmacokinetics (PK) and pharmacodynamics of drugs, thereby increasing the risk of ADRs. One of these diseases is heart failure (HF). Most studies of PK changes were conducted among patients with LVEF from 40 to 45 %, and excluded patients with concomitant diseases that could affect the PK of drugs (for example, serious liver and / or kidney diseases), therefore in polymorbid patients, trial findings may not be applicable. HF may be associated with a decrease in bioavailability, a decrease in volume of distribution, a change in the activity of cytochrome P450 isoenzymes, etc. Individual dose and dosage regimen adjustment can significantly reduce risks, improve the quality of medical care and improve the prognosis in patients with heart failure.
Author Ostroumova, O. D.
Pereverzev, A. P.
Author_xml – sequence: 1
  givenname: A. P.
  orcidid: 0000-0001-7168-3636
  surname: Pereverzev
  fullname: Pereverzev, A. P.
  organization: FSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation
– sequence: 2
  givenname: O. D.
  orcidid: 0000-0002-0795-8225
  surname: Ostroumova
  fullname: Ostroumova, O. D.
  organization: FSBEI FPE «Russian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation; FSAEI HE I. M. Sechenov First MSMU MOH Russia (Sechenovskiy University)
BookMark eNo9kMlKRDEQRYMoOH6D-YFoxpfEnYgTCLrQdahOKm20fWmSp-Df-9ppVcXl1qE4-2R7rCMSciz4ibLa-VNpnGPcCM8kl4JpZhQzfovsyUE45rRV2_P-V9olR72XBdfaGq6s3SPLG4Q20Qxl9d6QQqdAW-mvcxKn2mjNFNIHto40tfclbTjnpY79hD5sDsUZXdcJx6nAisZnGJfYaRnp-hnaG8T6WkacSuyHZCfDquPR7zwgT1eXjxc37O7--vbi_I5FMSjPrF6oqBXIKJTxPIMxOgPikLLlyQjnpEkpe5eTVTJxrhfSDjJm5FkLLtUBuf3hpgovYd3KG7TPUKGE76C2ZZjfLnGFIfKopAc9KMwaRFq4mSaszN5Kjp7PLPvDiq323jD_8wQP3_rDxmzYmA0b_UEHo4Lx6guS6noi
Cites_doi 10.1371/journal.pone.0079603
10.1023/A:1015802101272
10.2165/00003088-197601060-00001
10.1016/j.jjcc.2011.12.006
10.2165/00003088-198815020-00002
10.1038/ki.1984.153
10.1007/BF02395198
10.1007/s40262-014-0189-3
10.1021/mp060042f
10.1248/bpb.31.976
10.18535/jmscr/v5i7.71
10.1152/ajprenal.00476.2015
10.30895/2312-7821-2021-9-1-15-24
10.2165/00003495-200262080-00016
10.1007/s13539-013-0105-y
10.1046/j.0306-5251.2001.01410.x
10.1016/j.ijpharm.2019.05.041
10.1007/s40262-012-0029-2
10.4103/0973-8398.102938
10.1007/s002280050110
10.1111/bcp.13760
10.1016/j.jacc.2007.07.016
10.1016/0009-9236(95)90223-6
10.1248/bpb.29.2267
10.1016/j.ijcard.2016.09.015
10.18565/pharmateca.2020.5.77-84
10.1016/0002-9149(86)90995-1
10.2165/00003088-197601020-00005
10.1136/hrt.72.2_Suppl.S40
10.1159/000137299
10.1016/0002-8703(87)90217-1
10.1093/eurjhf/hft129
10.1016/S0002-9343(98)00111-9
10.1023/A:1016212804288
10.1146/annurev.pa.19.040179.002311
ContentType Journal Article
DBID AAYXX
CITATION
DOA
DOI 10.37489/2588-0519-2021-4-53-59
DatabaseName CrossRef
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2618-8473
EndPage 59
ExternalDocumentID oai_doaj_org_article_c0c329a463ef4a1db804b172f9720e90
10_37489_2588_0519_2021_4_53_59
GroupedDBID AAYXX
ALMA_UNASSIGNED_HOLDINGS
CITATION
GROUPED_DOAJ
ID FETCH-LOGICAL-c1639-74b3c43a2c13590fa554faee6df70d518825ddf98fd732d004b2762cfe0f41023
IEDL.DBID DOA
ISSN 2588-0519
IngestDate Fri Oct 03 12:53:22 EDT 2025
Sat Nov 29 05:01:00 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
Russian
License https://www.clinvest.ru/jour/about/editorialPolicies#openAccessPolicy
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1639-74b3c43a2c13590fa554faee6df70d518825ddf98fd732d004b2762cfe0f41023
ORCID 0000-0001-7168-3636
0000-0002-0795-8225
OpenAccessLink https://doaj.org/article/c0c329a463ef4a1db804b172f9720e90
PageCount 7
ParticipantIDs doaj_primary_oai_doaj_org_article_c0c329a463ef4a1db804b172f9720e90
crossref_primary_10_37489_2588_0519_2021_4_53_59
PublicationCentury 2000
PublicationDate 2022-02-13
PublicationDateYYYYMMDD 2022-02-13
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-13
  day: 13
PublicationDecade 2020
PublicationTitle Kachestvennai͡a︡ klinicheskai͡a︡ praktika
PublicationYear 2022
Publisher Izdatelstvo OKI
Publisher_xml – name: Izdatelstvo OKI
References ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref42
ref41
ref22
ref21
ref43
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
References_xml – ident: ref37
– ident: ref11
  doi: 10.1371/journal.pone.0079603
– ident: ref23
  doi: 10.1023/A:1015802101272
– ident: ref5
– ident: ref13
  doi: 10.2165/00003088-197601060-00001
– ident: ref26
  doi: 10.1016/j.jjcc.2011.12.006
– ident: ref14
  doi: 10.2165/00003088-198815020-00002
– ident: ref20
– ident: ref32
  doi: 10.1038/ki.1984.153
– ident: ref24
  doi: 10.1007/BF02395198
– ident: ref15
  doi: 10.1007/s40262-014-0189-3
– ident: ref29
  doi: 10.1021/mp060042f
– ident: ref41
  doi: 10.1248/bpb.31.976
– ident: ref17
  doi: 10.18535/jmscr/v5i7.71
– ident: ref27
  doi: 10.1152/ajprenal.00476.2015
– ident: ref3
  doi: 10.30895/2312-7821-2021-9-1-15-24
– ident: ref34
  doi: 10.2165/00003495-200262080-00016
– ident: ref10
  doi: 10.1007/s13539-013-0105-y
– ident: ref42
  doi: 10.1046/j.0306-5251.2001.01410.x
– ident: ref31
  doi: 10.1016/j.ijpharm.2019.05.041
– ident: ref12
  doi: 10.1007/s40262-012-0029-2
– ident: ref36
  doi: 10.4103/0973-8398.102938
– ident: ref7
  doi: 10.1007/s002280050110
– ident: ref16
  doi: 10.1111/bcp.13760
– ident: ref25
  doi: 10.1016/j.jacc.2007.07.016
– ident: ref30
– ident: ref2
– ident: ref38
– ident: ref8
  doi: 10.1016/0009-9236(95)90223-6
– ident: ref19
  doi: 10.1248/bpb.29.2267
– ident: ref4
  doi: 10.1016/j.ijcard.2016.09.015
– ident: ref1
  doi: 10.18565/pharmateca.2020.5.77-84
– ident: ref39
  doi: 10.1016/0002-9149(86)90995-1
– ident: ref21
– ident: ref43
  doi: 10.2165/00003088-197601020-00005
– ident: ref9
  doi: 10.1136/hrt.72.2_Suppl.S40
– ident: ref33
  doi: 10.1159/000137299
– ident: ref40
  doi: 10.1016/0002-8703(87)90217-1
– ident: ref6
  doi: 10.1093/eurjhf/hft129
– ident: ref18
  doi: 10.1016/S0002-9343(98)00111-9
– ident: ref28
  doi: 10.1023/A:1016212804288
– ident: ref22
  doi: 10.1146/annurev.pa.19.040179.002311
– ident: ref35
SSID ssib044750377
ssj0002874179
Score 2.1721952
Snippet The use of many drugs is associated with the risk of adverse drug reactions (ADRs), including those that increase mortality and / or morbidity and / or seek...
SourceID doaj
crossref
SourceType Open Website
Index Database
StartPage 53
SubjectTerms безопасность
лекарственно-индуцированные заболевания
лекарственные средства
нежелательные реакции
сердечная недостаточность
фармакокинетика
Title Heart failure as a risk factor of adverse drug reactions. Part 1: potential changes in pharmacokinetics
URI https://doaj.org/article/c0c329a463ef4a1db804b172f9720e90
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2618-8473
  dateEnd: 20241231
  omitProxy: false
  ssIdentifier: ssj0002874179
  issn: 2588-0519
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2618-8473
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssib044750377
  issn: 2588-0519
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELZQhRAL4inKSx5Yozq28zAboFYdaNUBpG6Wn1VBaqs2ZeS3c5cE1I2FJYOVxNHni-8uufs-Qu5zzlngqU08uM9Ewo6XWOlUUvA8IvtKmZlateSlGI_L6VRNdqS-sCasoQdugOs55gRXRuYiRGlSb0smLXjdqAqYRdXZOivUTjIFloQsdky0HZbv9SekAqW2UGkuA9PAuKUp9qrZV3q_g2A0HHKqJBMJspfuuKodRv_a9QyOyVEbM9LH5llPyN56e0oORu1f8TMyG4K5VjSaOdaYU7OhhmLJOG3EdOgyUoO6y5tA_Xo7oxAnusbc6AQvTB_oallh2RDM0nQCb-h8QVctrfUHzIJszufkbdB_fR4mrYBC4iDMAsClFU4Kw10qMsWigdghmhByHwvmkYqNZ95HVUZfCO7hfbEcNkcXA4sSOR0uSGexXIRLQnNepswG4bwQ0gVj0xKJmWF_kNZKlXcJ-8FKrxqeDA35RQ2vRng1wqsRXi11JnSmuuQJMf09HYmu6wFYft0uv_5r-a_-4ybX5JBjVwPqvIgb0qnW23BL9t1nNd-s72rLguPoq_8NNwnL-w
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heart+failure+as+a+risk+factor+of+adverse+drug+reactions.+Part+1%3A+potential+changes+in+pharmacokinetics&rft.jtitle=Kachestvennai%CD%A1a%EF%B8%A1+klinicheskai%CD%A1a%EF%B8%A1+praktika&rft.au=A.+P.+Pereverzev&rft.au=O.+D.+Ostroumova&rft.date=2022-02-13&rft.pub=Izdatelstvo+OKI&rft.issn=2588-0519&rft.eissn=2618-8473&rft.issue=4&rft.spage=53&rft.epage=59&rft_id=info:doi/10.37489%2F2588-0519-2021-4-53-59&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_c0c329a463ef4a1db804b172f9720e90
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2588-0519&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2588-0519&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2588-0519&client=summon